Second Circuit Finds “Product Hopping” By a Pharmaceutical Company to Violate Antitrust Laws
In New York v. Actavis PLC, No. 14-4624 (2nd Cir. May 22, 2015), the United States Court of Appeals for the Second Circuit became the first appellate court to address a pharmaceutical industry practice known as “product hopping.”
This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.
Copy link to share post